These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34756316)

  • 1. A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis.
    Jiménez-Morales A; Cáliz R; Aceituno S; Prades M; Blanch C
    Reumatol Clin (Engl Ed); 2021 Nov; 17(9):536-542. PubMed ID: 34756316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cost-Consequence Analysis of the Preferential Use of Secukinumab Versus Adalimumab for the Treatment of Psoriatic Arthritis.
    Jiménez-Morales A; Cáliz R; Aceituno S; Prades M; Blanch C
    Reumatol Clin (Engl Ed); 2020 Jul; ():. PubMed ID: 32693948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
    J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
    McInnes IB; Behrens F; Mease PJ; Kavanaugh A; Ritchlin C; Nash P; Masmitja JG; Goupille P; Korotaeva T; Gottlieb AB; Martin R; Ding K; Pellet P; Mpofu S; Pricop L;
    Lancet; 2020 May; 395(10235):1496-1505. PubMed ID: 32386593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
    Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
    Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany.
    Gandjour A; Ostwald DA
    Appl Health Econ Health Policy; 2020 Feb; 18(1):109-125. PubMed ID: 31701482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superior effect of adalimumab versus secukinumab on ultrasound-confirmed synovitis in psoriatic arthritis: comprehensive evidence from musculoskeletal ultrasound and clinical assessments.
    Wang Y; Xiao Y; Zhang L; Li F; Hu H; Peng X; Gao J; Yang M; Yan W; Qiu L; Li W
    J Dermatolog Treat; 2024 Dec; 35(1):2411849. PubMed ID: 39370135
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Schjødt Jørgensen T; Gudbjornsson B; Lederballe Grøn K; Aarrestad Provan S; Michelsen B; Lund Hetland M; Wallman JK; Nordström D; Trokovic N; Love TJ; Krogh NS; Askling J; Jacobsson LTH; Kristensen LE
    Rheumatology (Oxford); 2021 Aug; 60(8):3635-3645. PubMed ID: 33367900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis.
    Lu C; Wallace BI; Waljee AK; Fu W; Zhang Q; Liu Y
    Semin Arthritis Rheum; 2019 Dec; 49(3):381-388. PubMed ID: 31272807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
    Kirson NY; Rao S; Birnbaum HG; Kantor E; Wei RS; Cifaldi M
    J Med Econ; 2013; 16(4):479-89. PubMed ID: 23339434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis.
    Betts KA; Griffith J; Friedman A; Zhou ZY; Signorovitch JE; Ganguli A
    Curr Med Res Opin; 2016; 32(4):721-9. PubMed ID: 26743448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective.
    Purmonen T; Puolakka K; Bhattacharyya D; Jain M; Martikainen J
    Cost Eff Resour Alloc; 2018; 16():56. PubMed ID: 30479574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison.
    Strand V; Betts KA; Mittal M; Song J; Skup M; Joshi A
    Rheumatol Ther; 2017 Dec; 4(2):349-362. PubMed ID: 28762213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain.
    Schweikert B; Malmberg C; Núñez M; Dilla T; Sapin C; Hartz S
    BMJ Open; 2020 Aug; 10(8):e032552. PubMed ID: 32792421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals.
    Pham PA; Dressler C; Eisert L; Nast A; Werner RN
    Rheumatol Int; 2019 Apr; 39(4):605-618. PubMed ID: 30684041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-efficacy of biologic therapies for psoriatic arthritis from the perspective of the Taiwanese healthcare system.
    Yang TS; Chi CC; Wang SH; Lin JC; Lin KM
    Int J Rheum Dis; 2016 Oct; 19(10):1002-1009. PubMed ID: 26404916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service.
    Puig L; Notario J; Jiménez-Morales A; Moreno-Ramírez D; López-Ferrer A; Gozalbo I; Prades M; Lizán L; Blanch C
    J Dermatolog Treat; 2017 Nov; 28(7):623-630. PubMed ID: 28784002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
    Br J Dermatol; 2020 Aug; 183(2):294-302. PubMed ID: 32124442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.
    McInnes IB; Nash P; Ritchlin C; Choy EH; Kanters S; Thom H; Gandhi K; Pricop L; Jugl SM
    J Comp Eff Res; 2018 Nov; 7(11):1107-1123. PubMed ID: 30230361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.